ArticleDrug delivery2026
Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy.
Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial recombinant high-density protein nanocarriers for precision drug delivery.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein A-I (ApoA-I) mimetic peptides have garnered attention as potential anticancer agents owing to their role in cholesterol metabolism and ability to interact with the SR-BI receptor. However, their tendency to form lipid-bound structures in circulation limits their tumor-targeting therapeutic potential and raises the risk of off-target effects. In this study, we engineered a stimuli-responsive ApoA-I mimetic peptide by incorporating reactive oxygen species (ROS) -responsive amino acid derivatives into its sequence. Under normal physiological conditions, the peptide adopted a disordered conformation, minimizing nonspecific interactions. In contrast, the exposure to the tumor microenvironment, which is characterized by low pH and elevated ROS, could trigger a conformational transition to a structured
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.